Tagged with AstraZeneca

AstraZeneca   AstraZeneca’s Country President for Turkey discusses their efforts to build scientific leadership in Turkey in line with their global strategy and her hopes for the market access and public-private partnership environment in the coming years. The main value of AstraZeneca is putting the patient first and this is the…

basic research Professor Burak Erman, the leader of the Drug Research Center at Koç University, and his colleague Hakan Orer, discuss the early activities of the center as a catalyst for collaboration and communication between the pharmaceutical industry and academic sciences in Turkey, as well as the center’s achievements so far, including…

AstraZeneca Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels, with an emphasis on the complexities of the Peruvian market. What were your initial priorities when you became head of…

UCB UCB’s managing director for Turkey and the MEA region discusses UCB’s leading patient centricity, how UCB is addressing gaps in the Turkish healthcare system surrounding epileptic patients, and the company’s plan for regional expansion through partnerships. Given your patient centricity and UCB’s unique perspective, how would you assess the sectors approach…

UAE How quickly can a country truly transform its healthcare system, while making it sustainable for the future? The mindset of Emiratis is that anything that is feasible and beneficial for the country should and will be done, regardless of the cost. This is why health authorities have been moving at…

Generics The Country President of AstraZeneca Philippines discusses the company’s new growth strategy, the need for affordable product pricing, and the growing knowledge initiatives the companies is producing in order to tackle the lack in qualified medical practitioners in the Philippines. When AstraZeneca’s global CEO Pascal Soriot took office late 2012,…

partnering David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic areas. In what way do you think the pharmaceutical industry can act as an engine of economic recovery and development…

UAE Samer Al Hallaq, Gulf President of AstraZeneca, speaks about the company’s strategy to align its portfolio with the increasing presence of lifestyle diseases like diabetes, and how innovation is the driving force behind continued growth for the future.   Let’s begin by speaking a little bit about AstraZeneca’s global focus…

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

Government Regulation You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is a highly developed economy to start with; it is a very established market, with a very good healthcare system. The…

Baltic You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see for AstraZeneca in pushing this development forward? AstraZeneca has a significant R&D presence in Sweden. We currently have more than 2,300 researchers at our…

AstraZeneca Australia You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at the overall market, the biggest changes have been the various reforms to the Pharmaceutical Benefits Scheme (PBS). PBS reform started…